Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;266(6):1429-1438.
doi: 10.1007/s00415-019-09278-0. Epub 2019 Mar 16.

Heterogeneity in costs and prognosis for acute ischemic stroke treatment by comorbidities

Euna Han #  1 , Tae Hyun Kim #  2 , Heejo Koo  1 , Joonsang Yoo  3 , Ji Hoe Heo  3 , Hyo Suk Nam  4
Affiliations

Heterogeneity in costs and prognosis for acute ischemic stroke treatment by comorbidities

Euna Han et al. J Neurol. 2019 Jun.

Abstract

Objective: Comorbidities are prevalent among stroke patients. The current study assesses the variations in cost and stroke prognosis by concurrent comorbidities in patients with acute ischemic stroke.

Methods: The Charlson comorbidity index was used as the composite comorbidity level (0 none, 1 mild, 2 moderate, and ≥ 3 severe). Outcomes included modified Rankin Scale (mRS) at 3 months and 1-year mortality and stroke recurrence. We utilized a multivariate log-normal model for cost, a proportional Cox hazards model for outcomes, and a decision analytic model for the excess cost per unit change in outcome probability compared with the no-comorbidity group.

Results: A total of 3605 consecutive patients were enrolled. At 3 months, the severe comorbidity group was 0.32 times less likely to have mRS ≤ 2, and were 4.86 times more likely to die from stroke than the no-comorbidity group. Within 1 year, the severe comorbidity group showed 10.36 and 3.38 times higher likelihoods of death from stroke and stroke recurrence than the no-comorbidity group. The incremental cost was 4376 in 3 months and 7074 USD in 1 year for the severe comorbidity group, and 985 in 3 months and 1265 USD in 1 year for the mild comorbidity group compared to the no-comorbidity group.

Conclusion: The excess cost per unit increase of a short-term good prognosis was largest for the severe comorbidity group. Patients with severe comorbidities showed poor prognosis and large health expenditure. Assessing comorbidity level is crucial for better prediction of outcomes and excess cost.

Keywords: Comorbidity; Excess cost; Heterogeneity; Ischemic stroke; Prognosis.

PubMed Disclaimer

References

    1. Feigin VL (2015) Update on the global burden of ischaemic and haemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiol 45(3):161–176 - DOI
    1. Feigin VL, Norrving B, Mensah GA (2017) Global burden of stroke. Circ Res 120(3):439–448 - DOI
    1. Hankey GJ (2003) Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 16(1):14–19 - DOI - PubMed
    1. Kostulas N, Markaki I, Cansu H, Masterman T, Kostulas V (2009) Hyperglycaemia in acute ischaemic stroke is associated with an increased 5-year mortality. Age Ageing 38(5):590–594 - DOI - PubMed
    1. Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA et al (2015) Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiol 45:161–176 - DOI

MeSH terms

LinkOut - more resources